Pfizer Gains on Drug Pricing Concessions and Tariff Relief

26 days ago

Multiple Speakers

"Pfizer is your number one gainer in the S&P with that 7% gain. The company agreed to lower drug prices in exchange for relief on tariffs and will get a three-year grace period from President Trumps pharma tariff."

Pfizer experienced a notable 7% gain following announcements related to lower drug pricing and a three-year grace period from pharmaceutical tariffs, which is positively impacting the broader healthcare sector.

Related Stocks